Pharmaceuticals
Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"
BEJING, Sept. 27, 2021 /PRNewswire/ -- On September 25, 2021 in Beijing, China, the "Global Drug Information Platform for Rare Diseases" was successfully kicked off at Ali Center inBeijing. Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressin...
2021-09-27 21:00
4007
Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis
SEOUL, South Korea, Sept. 27, 2021 /PRNewswire/ -- Immunoforge (Co-CEOs Sung-min Ahn,Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 has received Orphan Drug Designation (ODD) from the U.S. FDA for th...
2021-09-27 21:00
1903
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference
* Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. * No SAE related to Silmitasertib was reported. * Silmitasertib is a host-directed antiviral and an anti-inflammatory investigational therapy expected to be effective against eme...
2021-09-27 19:20
3411
Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC
* Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in theAtlanta, GA, United States * AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments. * Seegene MDx system will efficiently access a wide ...
2021-09-27 19:02
3362
Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis
STOCKHOLM, Sept. 27, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start...
2021-09-27 17:37
2035
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-09-27 08:00
4565
Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients
SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that onSeptember 22 the Brazilian Health Regulatory Agency (ANVISA) ...
2021-09-26 23:09
6517
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote ...
2021-09-26 10:12
2531
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 24, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
2021-09-24 14:09
2465
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines
2021-09-24 13:56
4724
Broncus Lists on Main Board of HKEx
HONG KONG, Sept. 24, 2021 /PRNewswire/ -- On September 24, Broncus (02216.HK), a pioneer in the field of interventional pulmonology inChina, was successfully listed on the main board of the Hong Kong Stock Exchange. Broncus, founded in 2012, is a medical device company focused on the development...
2021-09-24 11:52
6738
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
2021-09-24 09:18
4171
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
- Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine - NanoFlu™ vaccine candidate induced significantly enhanced cell-mediated immune responses - NanoFlu was well-tolerated with a comparable safety profile...
2021-09-24 08:47
6193
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis
SAN FRANCISCO and SUZHOU, China, Sept. 24, 2021 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major d...
2021-09-24 08:00
4325
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
* Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedic...
2021-09-23 21:59
8159
Nanoform Shortlisted For The European Small and Mid-Cap Awards 2021
HELSINKI, Sept. 23, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has made the shortlist in the `Star of Innovation' category of the 9th annual European Small and Mid-Cap Awards. The nomination is based on Nanoform being a listed com...
2021-09-23 20:15
1805
BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO "Dr. Louis St. L. O'Dea" as CMO of BIORCHESTRA
BOSTON, Sept. 23, 2021 /PRNewswire/ -- BIORCHESTRA is a bio-tech company focused on the identification of novel targets in neurodegenerative diseases using RNA-based therapeutics. To access these novel targets, BIORCHESTRA has also developed a proprietary nanoparticle formulation to deliver RN...
2021-09-23 20:00
3248
Hainan Boao Lecheng International Medical Tourism Pilot Zone holds event to attract Japanese investment
The event is co-organized by Winhealth Pharma BOAO, China, Sept. 23, 2021 /PRNewswire/ -- The Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng Pilot Zone")'s virtual promotional event to explain the favorable investment policies put in place for Japanese businesses, hosted ...
2021-09-23 16:15
3434
AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials
SINGAPORE, Sept. 23, 2021 /PRNewswire/ -- Singapore's cancer population may benefit from improved access to cutting-edge clinical trials through InSite Feasibility - Oncoshot's new digital platform that facilitates the efficient completion of oncology feasibility studies supported by near real-ti...
2021-09-23 16:07
4400
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-09-23 08:00
4583
Week's Top Stories
Most Reposted
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 290 media titles]
2026-07-23 16:00
MetaOptics to Deploy its Direct Laser Writer at the University of Arizona's Center of Semiconductor Manufacturing to Advance its U.S. Expansion
[Picked up by 287 media titles]
2026-07-22 07:30Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
[Picked up by 286 media titles]
2026-07-20 11:00
Most Read
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
2026-07-17 18:18
13066
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
10152